Alan Remen Chief Executive Officer

1

Alan RemenChief Executive Officer

www.myostimpacers.com

ENABLING THE HEART TO SELF-REGENERATE


Transformational IP

MyoStim’s patents hold the pioneering ability to convert stem cells to heart muscle cells through electrical stimulation replicating the body's own natural method of creating a heart from stem cells.

2

www.myostimpacers.com 3

Validation“This invention could be regarded in the

future as one of the most important developments in the fight to reduce

death from heart failure“

Dr. Juan Chachques, Director of Surgical and Clinical Research at

Broussais and Pompidou Hospitals in Paris, France

"This truly has the potential to be a landmark invention in the field of

heart failure treatment"

Nov 6th 2008

David Holmes, M.D., Chairman of Cardiology, Mayo Clinic


Business Model

MyoStim has a distinct advantage in its business model. The company has identified the right product mix that will supply it with revenue streams starting from its first year of operations and moving on as it expands and obtains FDA approval for its Heart Repair Pacemaker.


MyoStim IntroductionMyoStim is developing a set of products to

target three market opportunities, leveraging our IP related to electrical stimulation.

2


Markets


Investment Opportunity $5.5 million launches the MyoStim Lab and Limb Stimulators

that will finance the $15 million clinical trials for the Heart Stimulator

Cell culture industry is $4.97 billion today on the way to be $20 billion in 7 years - immediately addressable: $480M

Limb ischemia market exceeds $2.2 billion worldwide today -Immediately addressable - $2B

The heart failure market exceeds $40 billion today. CRT/ICD pacers alone - $4.2 billion. CHF drugs $8 billion – immediately addressable $4.2B.


Cell Culture Stimulator1. Doubles the production of

cell cultures with half the amount of growth factors & media

2. Converts pluripotent stem cells to cardiomyocytes (beating heart muscle cells)

3. Reduces use of animal based products (FDA recommendation)

Product Line1

2

3


Cell CultureMarket


Blood Flow Stimulator – Limb Salvage (PAD)

3

2

3

Product Line

1. Stimulates muscle tissue or muscle scar tissue to activate the release of angiogenic (blood vessel forming) proteins.

2. Forms new blood vessels in ischemic or scarred areas

3. Induces reperfusion


Peripheral Artery Disease (PAD)

Market


Implantable Pacemaker – REPAIRS the heart

1. Recruits stem cells to damaged area

2. Converts recruited cells into heart muscle cells

3. Stimulates the creation of new blood vessels

4. Increases contraction strength of muscle

5. Ensures heart remains on beat

Product Line1

2

3


Cardiac Rhythm Management (CRM)

Market


2017

2013

Cell Culture Stimulator

Blood Flow Stimulator

Pacemaker

Revenue

Costs

leases/pay-per-use of cell culture stimulators

Sales / lease of blood flow stimulators

pacemaker implantations revenue

marketing, manufacturing, legal

marketing, mfg, clinical trials, distribution

Product Roll-out

Revenue

Costs

Revenue

Costs marketing, mfg., clinical trials, distribution


RegulatoryClinical/Regulatory Milestones

2012 2013 2014 2015 2016 2017 2018

Lab Stimulator

Blood Flow Stimulator

Pacemaker

No Clinical Studies Required

Product Dev

Pre-Clinical Testing OUS

Human Use/ Feasibility Trial

CE Mark OUS Commercialization

510(k) Approval

Product Development

Pre-Clinical Testing

OUS Human Use/

Feasibility TrialCE Mark OUS

Commercialization

IDE Trial in US PMA Approval

US Commercialization for Limb Salvage

Lab-Use Approval &

Commercialization

Product Dev


2010 sales estimated $2.5 million

Cell Culture Industry

2010 sales = $25.9 million

Blood Flow Stimulation Market

Competition

• Offers similar electrostimulation product to research laboratories • Ability to culture a variety of cells that are electrically coupled in vivo• Shown to only marginally improve cell proliferation• Demonstrated lack of marketing expertise• Willingness of laboratories to purchase the competitively inferior product

proves that there is an immediate market

• SmartPReP system allows physicians to rapidly prepare highly concentrated, autologous Platelet Rich Plasma (PRP) Enriched with growth factors to naturally stimulate the body's healing

process for bone and soft tissue wounds• SmartPReP 2 BMAC technology platform, a point-of-care device

Requires 15 minutes to process and concentrate adult stem cells from a small aspirate of autologous bone marrow

• Both applications have shown promising results in the treatment of cardiovascular and peripheral artery disease


Cardiac Rhythm ManagementPotential Exits

2010 Overall Revenues: $15.8 billion2010 Cardiac Rhythm Revenues: $5.268 billion

Core Businesses: Cardiac Rhythm Management, Cardiac surgery, Neurological and Diabetes, Vascular and Spinal/Navigation/ENT

2010 Revenues: $5.16 billion2010 Cardiac Rhythm Revenues: $3 billion

Core Businesses: Cardiac Rhythm Management, Atrial Fibrillation, Neuromodulation, Cardiovascular

2010 Revenues: $300 million2010 Cardiac Rhythm Revenues: $300 million

Core Businesses: Cardiac Rhythm Management

2010 Revenues: $7.8 billion2010 Cardiac Rhythm Revenues: $2.18 billion

Core Businesses: Cardiovascular Group, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology/Women’s Health, Neuromodulation


$ Clinical IP

CompetitiveAdvantage


$ Clinical IP

Cell Culture Stimulator

Without Stimulation With Stimulation



$ Clinical IP

Blood Flow Stimulator• Stimulates Angiogenesis

• Stimulates Arteriogenesis

• Improves wound healing

• Less painful treatment than competing products


20m

100m

Pacemaker• Stimulates heart muscle

growth

• Significant improvement in patient health


$ IP

Scientific Advisory Board Composed of a number of leading scientists who either hold patents for MyoStim use or are working on potentially new patentable medical innovations.

Patent Due DiligenceLegal patent reviews on file that MyoStim has a patent portfolio likely to stop infringers and are free to practice our methods and products in clinical trials without worry of infringing on anyone else’s patents.

Clinical


Patent # Patent Description Life

US 6,988,004 Method for Inducing Angiogenesis by Electrical Stimulation 12 years

US 7,341,062 Method for Providing dynamic Cellular Cardiac Support 14 years

US 7,483,749 Method of Enhancing Myogenesis by Electrical Stimulation 15 years


FinancialsSelected Proforma (in millions of $)

2012 2013 2014 2015 2016

Sales $2.1 $6.4 $17.5 $40.2 $75.2

Gross 85% 91% 95% 95% 95%

EBITDA ($1.2) ($1.1) $4.0 $23.3 $52.5

Net ($1.2) ($1.2) $3.1 $13.7 $19.5

1 2 3 4 5 (10,000)

-

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

RevenueEBITDANet Income


Over 25 years as a serial entrepreneur forming and running companies. Has served as Chairman, CEO, President & VP Business Development, VP Sales & Marketing. Has experience in aerospace, agriculture, data communications, telecommunications, industrial instrumentation and out-sourced engineering services industries.

Mr. Remen earned his degree in Business from San Diego State University after his service in the United States Marine Corps.

Serial entrepreneur and founder of two medical device companies, where he served as Chairman, CEO, CTO and President. Founded World Medical Manufacturing Corporation in 1986, which was acquired by Arterial Vascular Engineering, Inc. In 1999, founded Bioheart, which later become a public traded company (BHRT).

Mr. Leonhardt holds an honorary Doctorate Degree in Biomedical Engineering from the University of Northern California.

Chief Executive Officer - Alan Remen

Chief Technical Officer - Howard Leonhardt

Management


Previous positions with Deloitte Consulting, GE Medical, and Guidant. At Guidant, Mr. Olson was a sales representative for the Cardiac Rhythm Management division working with physicians who implanted pacemakers, defibrillators, and cardiac resynchronization therapy devices that treat Congestive Heart Failure. As Vice President of Corporate Development at FoxHollow Technologies, Mr. Olson was a part of a company that went from $35M in sales to over $200M in sales, and lead much of the sale process to ev3 for $780M. ev3 was subsequently acquired by Covidien for $2.5B in 2010. Upon the acquisition of FoxHollow by ev3, serial entrepreneur and cardiology legend John B. Simpson (FoxHollow founder), recruited Mr. Olson to found Sawtooth Labs with him as it's founding CEO. Mr. Olson is a summa cum laude graduate in Computer Science, Information Systems, and Operations & Strategic Management from Boston College and an MBA graduate from Harvard University.

Chief Operating Officer - Bill OlsonActing VP Sales

Management


Dr. Abraham serves as a Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine of The Ohio State University College of Medicine. Dr. Abraham is an Adjunct Professor of Physiology and Cell Biology. He serves as Deputy Director for Clinical and Translational Research of Dorothy M. Davis Heart and Lung Research Institute. Dr. Abraham serves on the editorial boards of several major journals including the Journal of Cardiac Failure, Congestive Heart Failure, and Journal Watch Cardiology. He is also a Scientific Reviewer for such publications as Circulation, the European Heart Journal and the Journal of the American College of Cardiology. He served as Director of Cardiokine, Inc. He held faculty appointments at the University of Colorado, the University of Cincinnati, and the University of Kentucky. Dr. Abraham is a member of the committee to update the American College of Cardiology/ American Heart Association Heart Failure Guidelines. He has received grants from the National Institutes of Health, the American College of Cardiology, and the Aetna Quality Care Foundation . He has been recognized as one of the "Best Doctors in America" for six consecutive years. He earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiology and Heart Failure/Cardiac Transplantation at the University of Colorado Health Sciences Center.

Scientific Advisory BoardChairman – William T. Abraham, M.D., F.A.C.P., F.A.C.C


Scientific Advisory Board

Dr. Schwarz has served as Medical Director of the Cardiac Support Program and Co-Director of Cardiac Transplantation at Cedars-Sini.Dr. Schwarz is board certified in internal medicine by the American Board of Internal Medicine and in cardiology/cardiovascular diseases by the American Board of Internal Medicine in Cardiology/Cardiovascular Diseases. His primary clinical interests are end-stage heart failure, cardiac transplantation, interventional cardiology and sexual function in cardiac disease.A clinician and scientist, Dr. Schwarz has presented and lectured all over the world. He has written more than 70 articles for peer-reviewed publications and eight book chapters on cardiovascular medicine.Dr. Schwarz earned his medical degree from Philipps-University in Marburg, Germany, receiving medical doctor titles from Philipps-University Marburg and from the University of Vienna, Austria. He received his doctorate from the University of Technology in Aachen, Germany. Mr. Olson’s previous

Ernst Schwarz, MD, PhD, FESC, FACC, FSCAI


European Hospital Georges PompidouParis, FranceDr. Juan C. Chachques is the Director of Cardiac Research at the Alain Carpentier Foundation, and cardiac surgeon at the HEGP. He graduated of MD at the Faculty of Medicine of Rosario, Argentine. He obtained MS and PhD at the University of Paris, France. After clinical and surgical cardiologic training in Broussais Hospital of Paris, he gained expertise in experimental and clinical procedures for the treatment of heart failure. He developed Cardiac Bioassist surgical techniques, e.g. latissimus dorsi dynamic cardiomyoplasty, dynamic aortomyoplasty, atriomyoplasty. More recently he developed cell-based and tissue engineered procedures for myocardial support and regeneration, i.e. cellular cardiomyoplasty and bioartificial myocardium. He is a clinician and surgical scientist with expertise in myocardial diseases and valve repair procedures. He pursues his research interests in the integrative electrophysiology and cellular biology, the goal is to use in-vitro and in-vivo functional electrostimulation for cardiomyogenic stem-cell conditionning in order to create a dynamic cell based cardiac support. He is the founder and president of the Cardiac Bioassist Association. His further clinical research focuses on e-medecine and in the development of clinical trials for heart failure patients, e.g. the MAGNUM Trial: Myocardial Assistance by Grafting a New Upgraded bioartificial Myocardium.

Scientific Advisory BoardJuan C. Chachques


Research Professor in the Department of Surgery at the University of Utah. He formerly served as Research Associate Pittsburgh Medical Center of Cardiac Stem Cells Therapies of the McGowan Institute. Dr. Genovese received his M.D. from the School of Medicine of Buenos Aires University, where he also obtained his Ph.D. after completing a thesis on TGF-Beta, an important growth factor involved in cell development and regeneration. He has been Vice-President of the Tissue Engineering Society International and is a member, among other institutions, of the Latin American Biomaterials and Artificial Organs Society and a founding member of the Latin American Association of Tissues Banks. He is Honorary President of the Tissue Engineering Committee at the National Academy of Science and Medicine of China. Dr. Genovese is a member of the editorial board of J. Stem Cells and the advisory board of Basic and Applied Myology.

Scientific Advisory Board

Dr. Jorge Genovese


Funding

2012 – 2017Capture market share of cell culture & blood flow

stimulators while completing FDA

Phases I-III clinical studies

Exit Strategy5-7 year exit windowEnd Valuation = 4-5X

Revenue

Documents

Alan Remen Chief Executive Officer